JP2011500696A5 - - Google Patents

Download PDF

Info

Publication number
JP2011500696A5
JP2011500696A5 JP2010530052A JP2010530052A JP2011500696A5 JP 2011500696 A5 JP2011500696 A5 JP 2011500696A5 JP 2010530052 A JP2010530052 A JP 2010530052A JP 2010530052 A JP2010530052 A JP 2010530052A JP 2011500696 A5 JP2011500696 A5 JP 2011500696A5
Authority
JP
Japan
Prior art keywords
oxo
methyl
pyridinyl
disease
benzofuranyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010530052A
Other languages
English (en)
Japanese (ja)
Other versions
JP5255644B2 (ja
JP2011500696A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/079760 external-priority patent/WO2009052065A1/en
Publication of JP2011500696A publication Critical patent/JP2011500696A/ja
Publication of JP2011500696A5 publication Critical patent/JP2011500696A5/ja
Application granted granted Critical
Publication of JP5255644B2 publication Critical patent/JP5255644B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010530052A 2007-10-17 2008-10-14 置換されたn−フェニル−ビピロリジンカルボキサミド及びその治療上の使用 Expired - Fee Related JP5255644B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98060107P 2007-10-17 2007-10-17
US60/980,601 2007-10-17
PCT/US2008/079760 WO2009052065A1 (en) 2007-10-17 2008-10-14 Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof

Publications (3)

Publication Number Publication Date
JP2011500696A JP2011500696A (ja) 2011-01-06
JP2011500696A5 true JP2011500696A5 (https=) 2011-07-28
JP5255644B2 JP5255644B2 (ja) 2013-08-07

Family

ID=40243633

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010530052A Expired - Fee Related JP5255644B2 (ja) 2007-10-17 2008-10-14 置換されたn−フェニル−ビピロリジンカルボキサミド及びその治療上の使用

Country Status (25)

Country Link
US (1) US8618159B2 (https=)
EP (1) EP2212282B1 (https=)
JP (1) JP5255644B2 (https=)
KR (1) KR20100092441A (https=)
CN (1) CN101903339B (https=)
AT (1) ATE525350T1 (https=)
AU (1) AU2008312638B2 (https=)
BR (1) BRPI0818626A2 (https=)
CA (1) CA2702482C (https=)
CO (1) CO6190616A2 (https=)
CY (1) CY1112683T1 (https=)
DK (1) DK2212282T3 (https=)
ES (1) ES2374116T3 (https=)
HR (1) HRP20110953T1 (https=)
IL (1) IL205003A0 (https=)
MA (1) MA31855B1 (https=)
MX (1) MX2010004094A (https=)
MY (1) MY149650A (https=)
NZ (1) NZ584688A (https=)
PL (1) PL2212282T3 (https=)
PT (1) PT2212282E (https=)
RU (1) RU2477719C2 (https=)
SI (1) SI2212282T1 (https=)
WO (1) WO2009052065A1 (https=)
ZA (1) ZA201001946B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009052068A1 (en) 2007-10-17 2009-04-23 Sanofi-Aventis Substituted n-phenyl-bipyrrolidine ureas and therapeutic use thereof
CN101903342B (zh) * 2007-10-17 2012-11-21 赛诺菲-安万特 取代的n-苯基-吡咯烷基甲基吡咯烷酰胺及其作为组胺h3受体调节剂的治疗用途
CN101903340B (zh) * 2007-10-17 2013-03-27 赛诺菲-安万特 取代的n-苯基联吡咯烷羧酰胺及其治疗用途
AR074467A1 (es) 2008-12-05 2011-01-19 Sanofi Aventis Tetrahidropiran espiro pirrolidinonas y piperidinonas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento y/o prevencion de enfermedades del snc ,tales como alzheimer y parkinson, entre otras.
AR074466A1 (es) * 2008-12-05 2011-01-19 Sanofi Aventis Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3.
AR083718A1 (es) 2010-05-11 2013-03-20 Sanofi Aventis Fenil cicloalquil pirrolidina (piperidina) espirolactamas y amidas sustituidas, preparacion y uso terapeutico de las mismas
WO2011143162A1 (en) * 2010-05-11 2011-11-17 Sanofi Substituted n-heteroaryl bipyrrolidine carboxamides, preparation and therapeutic use thereof
WO2011143155A1 (en) * 2010-05-11 2011-11-17 Sanofi Substituted n-heteroaryl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof
JP5833105B2 (ja) 2010-05-11 2015-12-16 サノフイ 置換n−ヘテロアリールスピロラクタムビピロリジン類、その製造及び治療的使用
TW201206889A (en) 2010-05-11 2012-02-16 Sanofi Aventis Substituted N-alkyl and N-acyl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof
TW201206898A (en) * 2010-05-11 2012-02-16 Sanofi Aventis Substituted N-phenyl spirolactam bipyrrolidines, preparation and therapeutic use thereof
EP2569297A1 (en) 2010-05-11 2013-03-20 Sanofi Substituted n-heterocycloalkyl bipyrrolidinylphenyl amide derivatives, preparation and therapeutic use thereof
WO2012162291A1 (en) 2011-05-24 2012-11-29 The Wistar Institute Compositions and methods for modulating the activity of epstein-barr nuclear antigen 1
WO2014134391A1 (en) 2013-02-28 2014-09-04 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
AR094929A1 (es) 2013-02-28 2015-09-09 Bristol Myers Squibb Co Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
US7279491B2 (en) * 2002-10-23 2007-10-09 Janssen Pharmaceutica N.V. Phenylpiperidines and phenylpyrrolidines
US7223788B2 (en) * 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
DE10306250A1 (de) * 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU2006227815B2 (en) 2005-03-17 2011-09-22 Eli Lilly And Company Pyrrolidine derivatives as histamine H3 receptor antagonists
AU2006232871B9 (en) * 2005-04-01 2011-11-24 Eli Lilly And Company Histamine H3 receptor agents, preparation and therapeutic uses
EP1904442B1 (en) * 2005-07-01 2011-09-07 Eli Lilly And Company Histamine h3 receptor agents, preparation and therapeutic uses
CA2627234A1 (en) * 2005-10-27 2007-05-03 Ucb Pharma, S.A. Compounds comprising a lactam or a lactam derivative moiety, processes for making them, and their uses
CN101903340B (zh) * 2007-10-17 2013-03-27 赛诺菲-安万特 取代的n-苯基联吡咯烷羧酰胺及其治疗用途
WO2009052068A1 (en) * 2007-10-17 2009-04-23 Sanofi-Aventis Substituted n-phenyl-bipyrrolidine ureas and therapeutic use thereof
CN101903342B (zh) * 2007-10-17 2012-11-21 赛诺菲-安万特 取代的n-苯基-吡咯烷基甲基吡咯烷酰胺及其作为组胺h3受体调节剂的治疗用途

Similar Documents

Publication Publication Date Title
JP2011500696A5 (https=)
CA2702482A1 (en) Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
JP2011500694A5 (https=)
JP2011500693A5 (https=)
JP2007516941A5 (https=)
JP2011500697A5 (https=)
JP2011527333A5 (https=)
JP2010504344A5 (https=)
JP2011528658A5 (https=)
JP2007508358A5 (https=)
JP2010514829A5 (https=)
JP2005508349A5 (https=)
JP2007511504A5 (https=)
MX2010005717A (es) Derivados de isoxazolo-piridina.
JP2007508360A5 (https=)
JP2010500293A5 (https=)
JP2013510885A5 (https=)
TWI455934B (zh) 4-甲基-n-〔3-(4-甲基-咪唑-1-基)-5-三氟甲基-苯基-3-(4-吡啶-3-基-嘧啶-2-基胺基)-苯甲醯胺之鹽
JP2006505559A5 (https=)
JP2009534468A5 (https=)
JP2004534816A5 (https=)
JP2010529081A5 (https=)
JP2012505234A5 (https=)
HRP20151077T1 (hr) Derivati pirazola
JP2008543860A5 (https=)